CCM Biosciences has officially launched, unveiling over ten novel drug programs focused on precision oncology, rare diseases, autoimmune disorders, and age-related conditions. Co-founded by Dr. Raj Chakrabarti and Dr. Anisha Ghosh, the company has partnered with PMC Group to enhance its drug development processes through streamlined Chemistry, Manufacturing, and Control (CMC) activities. CCM’s portfolio features innovative treatments targeting significant medical needs, such as KRAS-driven cancers and therapies for genetic disorders, with several candidates nearing FDA filing. The firm has attracted over $25 million in funding and aims to leverage advanced drug discovery platforms for further development.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.prnewswire.com/news-releases/ccm-biosciences-launches-from-stealth-to-advance-portfolio-of-proprietary-first-in-class-therapies-and-companion-diagnostic-tests-across-multiple-therapeutic-areas-301912588.html
